Stephen Davis - 03 Jan 2023 Form 4 Insider Report for BELLICUM PHARMACEUTICALS, INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 03 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2023, 12:12:31 UTC
Prior SEC filing: 20 Dec 2022
Next SEC filing: 10 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Richard A. Fair, Attorney-in-Fact

Key filing fact

Stephen Davis filed Form 4 for BELLICUM PHARMACEUTICALS, INC on 05 Jan 2023.

Key facts

This page summarizes Stephen Davis's Form 4 filing for BELLICUM PHARMACEUTICALS, INC.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jan 2023, 12:12.

Change

Previous filing in this sequence was filed on 20 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLCM transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +74,739
Change %: +120%
Price: $0.000000
Shares after: 136,854
Date: 03 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date.